Pelareorep in Early-Stage HR+/HER2- Breast Cancer
In 2019, more than 3.7 million people in the US were living with breast cancer1. Building on the success of previous studies in which patients saw increased PD-L1 expression following pelareorep treatment, Oncolytics’ AWARE-1 clinical trial was designed to confirm pelareorep’s mechanism of action and examine its potential to synergize with immune checkpoint inhibitors using biomarker measurements such as CelTIL score, T cell infiltration and PD-L1 expression.
For additional details about this study, please visit the AWARE-1 clinical trial page.
- National Cancer Institute. (2021). Cancer Stat Facts: Female Breast Cancer. SEER Program, Surveillance, Epidemiology, and End Results. Retrieved April 5, 2023, from https://seer.cancer.gov/statfacts/html/breast.html.
Learn more about pelareorep’s potential to remodel the tumor microenvironment by enabling the influx of CD8+ and memory T cells into the tumor and training them to fight cancer.
For the latest updates on the AWARE-1 trial, click the link below.
For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.